Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Pre-Tax Margin

Income before tax as a percentage of revenue.

Owlet, Inc.NYSE: OWLT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -14.8%

Pre-tax margin was -14.8% in Q1 FY2026, down 29.2 pp from a year earlier. On a trailing-twelve-month basis it was -43.0%, down 28.6 pp year over year. Over 3 fiscal years it widened by 77.1 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-14.8%+19.9 pp QoQ
Last fiscal yearDec 2025
-37.5%-21.5 pp YoY
LTMMar 2026
-43.0%-28.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-29.2 pp——
1 year-21.5 pp——
3 years+77.1 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-37.5%
Year-over-year change
-21.5pp

Pre-Tax Margin vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 pre-tax margin of -43.0% is the 3rd highest of the 8 companies compared; the peer median is -145.7%.
  • Its year-over-year change of -28.6 pp is the 6th highest of 8, against a peer median of -4.4 pp.
  • Over three fiscal years its change of +77.1 pp compares with a peer median of -2.3 pp.
OWLT Competitors Peer median
Pre-Tax Margin for OWLT and competitors
Company Period LTM level YoY 3-year change
LNSRLENSAR, Inc.LTM Mar 202650.9% +150.1 pp-2.3 pp
ANIKAnika Therapeutics, Inc.LTM Mar 2026-8.8% -4.4 pp-12.0 pp
OWLTOwlet, Inc.LTM Mar 2026-43.0% -28.6 pp+77.1 pp
MXCTMaxCyte, Inc.LTM Mar 2026-121.2% -10.2 pp-81.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-145.7% +5.4 pp+218.1 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-876.7% +604.8 pp+13666.8 pp
AVRAnteris Technologies Global Corp.LTM Mar 2026-5116.2% -1836.7 pp-3970.6 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-8526.1% -217.6 pp+2294.9 pp
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding OWLT) -145.7%-4.4 pp-2.3 pp

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.84M69.2M54.01M78.06M105.71M
Cost of Revenue40.78M45.89M31.42M38.75M52.18M
Gross Profit35.06M23.31M22.59M39.31M53.53M
Gross Margin46.2%33.7%41.8%50.4%50.6%
Research & Development21.43M27.9M10.35M9.8M14.08M
Selling, General & Admin69.42M80.04M40.87M49.73M47.72M
Operating Expenses90.85M107.93M51.22M59.53M61.79M
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
EBITDA(42.71M)(75.53M)(27.49M)(9.47M)(35.64M)
EBITDA Margin-56.3%-109.1%-50.9%-12.1%-33.7%
Operating Income(55.79M)(84.62M)(28.63M)(20.22M)(8.26M)
Operating Margin-73.6%-122.3%-53.0%-25.9%-7.8%
Interest Income00000
Interest Expense27.83M1.1M3.19M1.63M3.42M
Other Income / Expenses(15.88M)5.31M(4.26M)7.74M(31.39M)
Income Before Tax(71.67M)(79.31M)(32.89M)(12.48M)(39.65M)
Pre-Tax Margin-94.5%-114.6%-60.9%-16.0%-37.5%
Income Tax Expense31K29K10K54K28K
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(39.68M)
Net Margin-94.5%-114.6%-60.9%-16.1%-37.5%
EPS (Basic)(12.47)(9.97)(4.53)(0.83)(2.24)
EPS (Diluted)(12.47)(9.97)(4.53)(0.83)(2.24)
Weighted Avg Shares7.87M7.95M8.28M15.11M562.5M
Weighted Avg Shares (Diluted)7.87M7.95M8.28M15.11M562.5M

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.